IL6 and myeloid sarcoma: In another study, IL-17 production in peripheral blood mononuclear cells from RR-MS patients treated with rituximab was lower than pre-treatment (without differences in IFN-γ), suggesting that this could be mediated by a reduced IL-6 production after B cell depletion (73).